Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime-avibactam : A prospective multicentric cohort study
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: This study aimed to evaluate the clinical and microbiological risk factors associated with mortality in patients treated with ceftazidime-avibactam for carbapenem-resistant Gram-negative bacterial infections.
METHODS: This multicentric prospective cohort study included hospitalized adult patients with a microbiologically confirmed infection treated with ceftazidime-avibactam for ≥48 hours. The clinical and microbiological risk factors for 30-day mortality were evaluated using a Cox regression model.
RESULTS: Of the 193 patients evaluated from the five tertiary hospitals, 127 were included in the study. Thirty-five patients (27.6%) died within 30 days. Infections with AmpC beta-lactamase-carrying bacteria were independently related to 30-day mortality (adjusted hazard ratio [aHR] 2.49, 95% confidence interval [CI] 1.28-4.84, P < 0.01) after adjusting for time from infection to antimicrobial prescription (P = 0.04). Further, these bacterial infections were also related to higher in-hospital mortality (aHR 2.17, 95% CI 1.24-3.78, P < 0.01). Only one patient developed resistance to ceftazidime-avibactam during treatment.
CONCLUSIONS: Treatment with ceftazidime-avibactam had worse clinical outcomes in patients with infections with bacteria with chromosomally encoded AmpC beta-lactamase. However, these findings should be confirmed in future studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Journal of global antimicrobial resistance - 36(2024) vom: 25. März, Seite 393-398 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arns, Beatriz [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jgar.2024.02.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368319571 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368319571 | ||
| 003 | DE-627 | ||
| 005 | 20240408232342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240212s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jgar.2024.02.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM368319571 | ||
| 035 | |a (NLM)38342378 | ||
| 035 | |a (PII)S2213-7165(24)00028-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arns, Beatriz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime-avibactam |b A prospective multicentric cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: This study aimed to evaluate the clinical and microbiological risk factors associated with mortality in patients treated with ceftazidime-avibactam for carbapenem-resistant Gram-negative bacterial infections | ||
| 520 | |a METHODS: This multicentric prospective cohort study included hospitalized adult patients with a microbiologically confirmed infection treated with ceftazidime-avibactam for ≥48 hours. The clinical and microbiological risk factors for 30-day mortality were evaluated using a Cox regression model | ||
| 520 | |a RESULTS: Of the 193 patients evaluated from the five tertiary hospitals, 127 were included in the study. Thirty-five patients (27.6%) died within 30 days. Infections with AmpC beta-lactamase-carrying bacteria were independently related to 30-day mortality (adjusted hazard ratio [aHR] 2.49, 95% confidence interval [CI] 1.28-4.84, P < 0.01) after adjusting for time from infection to antimicrobial prescription (P = 0.04). Further, these bacterial infections were also related to higher in-hospital mortality (aHR 2.17, 95% CI 1.24-3.78, P < 0.01). Only one patient developed resistance to ceftazidime-avibactam during treatment | ||
| 520 | |a CONCLUSIONS: Treatment with ceftazidime-avibactam had worse clinical outcomes in patients with infections with bacteria with chromosomally encoded AmpC beta-lactamase. However, these findings should be confirmed in future studies | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AmpC | |
| 650 | 4 | |a Carbapenem-resistance | |
| 650 | 4 | |a Ceftazidime–avibactam | |
| 650 | 4 | |a Enterobacteriaceae | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Pseudomonas aeruginosa | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a avibactam, ceftazidime drug combination |2 NLM | |
| 650 | 7 | |a Azabicyclo Compounds |2 NLM | |
| 650 | 7 | |a beta-Lactamase Inhibitors |2 NLM | |
| 650 | 7 | |a Ceftazidime |2 NLM | |
| 650 | 7 | |a 9M416Z9QNR |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 700 | 1 | |a Sorio, Guilherme Geraldo Lovato |e verfasserin |4 aut | |
| 700 | 1 | |a Vieceli, Tarsila |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Dariane |e verfasserin |4 aut | |
| 700 | 1 | |a Celestino de Souza, Ândrea |e verfasserin |4 aut | |
| 700 | 1 | |a Lamb Wink, Priscila |e verfasserin |4 aut | |
| 700 | 1 | |a Paes, Julia Hoefel |e verfasserin |4 aut | |
| 700 | 1 | |a David, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Barboza, Fernanda |e verfasserin |4 aut | |
| 700 | 1 | |a Hickmann, Stella |e verfasserin |4 aut | |
| 700 | 1 | |a Alves, Gustavo |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Antônio Cândido |e verfasserin |4 aut | |
| 700 | 1 | |a da Rosa, Anelise |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte Alves, Marcelle |e verfasserin |4 aut | |
| 700 | 1 | |a Massotti Magagnin, Cibele |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Zavascki, Alexandre Prehn |e verfasserin |4 aut | |
| 700 | 1 | |a Rigatto, Maria Helena |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of global antimicrobial resistance |d 2013 |g 36(2024) vom: 25. März, Seite 393-398 |w (DE-627)NLM237523876 |x 2213-7173 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2024 |g day:25 |g month:03 |g pages:393-398 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jgar.2024.02.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2024 |b 25 |c 03 |h 393-398 | ||